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miRNA can bind to many mRNA targets, thereby regulating around one-third of the genome (40, 66) . miRNAs are transcribed and processed in response to extracellular stimuli, or during developmental stages, in a tightly regulated manner. They are implicated in many cellular processes, including inflammation and cancer.
Several studies show variations in miRNA expression in human colorectal cancer (CRC), which largely depend on the origin and characteristics of the tumor (2, 59) .
Inflammatory conditions are increasingly being acknowledged to contribute to tumor formation. Inflammation is even included as the seventh hallmark of cancer development (13, 27) . Patients diagnosed with inflammatory bowel disease (IBD) have an 18% increased risk of developing a CRC during the following 30 years (71) .
Chronic inflammation is associated with an increased risk of progression to epithelial dysplasia and CRC in patients with IBD, but there is a limited understanding of the mechanisms that are involved in the transition from intestinal inflammation to cancer (4) .
The azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model is a widely used and well-characterized model of human colitis-associated cancer (CAC) (15, 23) . AOM/DSSinduced tumors display very similar histological and molecular features to human CRC (15) . Depending on the genetic background of the mice, the tumor-induction method comprises a single intraperitoneal injection of a carcinogen, AOM, followed by one or three cycles of DSS administration via the drinking water. DSS treatment leads to intestinal epithelial barrier disruption and the establishment of chronic inflammation. After 10 -20 wk, and only when AOM is administered, colorectal tumors grow in a manner that recapitulates the aberrant crypt foci-adenoma-carcinoma sequence seen in human CRC (15) . Using this mouse model, Greten et al. (23) and Grivennikov et al. (24) showed that interactions among tumor cells, the inflammatory microenvironment, and immune cells appear to be critical for tumor progression (52, 58) .
In the present study, we used this mouse model to establish miRNA expression profiles in mouse whole colon at early and late time points during inflammation and/or tumor growth. We identified 77 differentially expressed miRNAs, defined as miRNA landscape. Prediction algorithms and computational analyses based on ranked miRNA lists revealed potential regulation of genes that play essential roles in tumor growth or that are involved in key carcinogenesis networks or signaling pathways. We found that inflammation-triggered dysregulation of key miRNAs can affect the cancer-related PI3K/Akt and IGF-1 signaling pathways. In addition, we showed variations of miRNA expression patterns between epithelial and myeloid cell types during the periods preceding and spanning tumor growth.
MATERIALS AND METHODS
Animal procedures. Male C57Bl/6J mice (5 wk old) were obtained from Charles River Laboratories. Carcinogen (AOM; Sigma-Aldrich) was diluted in PBS and injected intraperitoneally at 12 mg/kg on the first day of the procedure. The animals were maintained on a standard rodent diet, and chronic inflammation was induced by three cycles of DSS (2%) administration via the drinking water for 5 days, followed by 16 days of regular water. On day 65 or day 100, mice were euthanized and the colons were excised, flushed with PBS, and 1) fixed as "Swiss rolls" (rectum part inside and cecal part outside) in 10% formalin at 4°C overnight and paraffin embedded (FFPE); 2) conserved in RNALater (Ambion-Applied Biosystems) until total RNA extraction; or 3) embedded as Swiss rolls in Tissue-Tek (Gentaur) and conserved at Ϫ80°C. For some animals, macroscopic tumors were dissected at day 100 and compared with adjacent tissue taken from an ϳ1-cm 2 surface area around the tumor. FFPE tissue sections (4 m) were stained with hematoxylin/eosin and observed by a pathologist.
Ethical statements. This study was carried out in strict accordance with the guidelines for the care and use animals set out by the European Union. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Liège (permit no. 1220).
RNA extraction. Colons were removed from the RNALater solution, wiped, and cut into small pieces. Homogenization/lysis was performed by using Tripur (Roche, Vilvoorde, Belgium) in a Qiagen Tissue Lyser with a stainless steel bead (Qiagen, Leiden, The Netherlands). Total RNA was extracted according to the manufacturer's instructions. Total RNAs were extracted from Caco-2 cells or sorted colon cell populations by using the miRNeasy mini Kit (Qiagen) according to the manufacturer's instruction.
miRNA microarray. miRNA microarray analysis was performed by Miltenyi Biotech using 1 g of total RNA per sample and MiRXplore (miRBase 13.0). Each RNA sample was hybridized in dual color to enable comparison with a commercial internal reference standard (miRXplore Universal Reference). The use of an internal reference enables the comparison of each sample or group with all others. The signal ratio of sample to internal reference was calculated. After examination of the raw data, miRNAs that did not show a Ͼ1.3-fold increase in expression above background levels in all four technical replicates of the 50 RNA samples were discarded from the analyses. In total, 211 miRNAs remained after this filtering process.
The miRXplore Universal Reference (Miltenyi Biotech) did not contain every miRNA present in the miRBase 13.0 database. Because the distribution of the ratio of miRNAs present in (172 over 211), or absent from (39 over 211), the Universal Reference was different, normalization of the ratios was performed separately on these two groups as follows: the ratios were log-transformed and then standardized (i.e., mean-subtracted and divided by the standard deviation, with the means and standard deviation calculated separately for the miRNA on each array).
Significant differences in miRNA expression under the two different conditions were detected via the Mann-Whitney U-test. Raw P values were then false discovery rate (FDR) adjusted for multiple testing by Benjamini and Hochberg's method. miRNAs with P Ͻ0.05 and at least 1.6-fold expression variation were considered to be significantly affected by the treatment.
All analyses were performed with use of MATLAB (The MathWorks, Natick, MA).
The data presented in this publication have been deposited in NCBI's Gene Expression Omnibus (18) and are accessible through GEO Series accession number GSE38443 (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?accϭGSE38443).
Identification of genes regulated by pools of miRNA. Given a ranked list of N miRNAs, a P value is associated to each gene that is a potential target of the miRNA in the list as follows: 1) the miRNAs targeting a particular gene are retrieved from TargetScan Version 5.0 (conserved species, http://www.targetscan.org) and miRanda software packages (43) , only genes predicted by the two algorithms are retained; (2) the sum of inverted ranks of the miRNAs targeting the gene is computed, where the inverted rank of a miRNA is defined as NϪiϩ1, with i being the rank of the miRNA in the ranked list of N miRNAs (i is taken as Nϩ1 for miRNAs not present in the ranked list); 3) this sum is then compared with equivalent sums obtained for 100,000 random sets of miRNAs (drawn from miRNAs present on the array) of the same size as the set of miRNAs targeting the gene, and the P value is calculated as the number of these 100,000 sums that are greater than the original sum; 4) the resulting P values for all the genes are FDR adjusted for multiple testing by the method of Benjamini and Hochberg.
These analyses were performed with in-house software developed in Python.
Reverse-transcription and real-time PCR. The miRCURY LNA Universal RT microRNA PCR system (Exiqon) was used to perform reverse transcription and quantification of miRNA. Primer sets specific for mmu-miR-223, mmu-miR-29c, mmu-miR-148a, mmu-miR-34a, mumiR-142-5p, mmu-miR-146a, mmu-miR-193, mmu-miR-216a, mmumiR-133a, mmu-miR-133b, mmu-miR-143, mmu-miR-145, hsa-miR-223, hsa-miR-133a, hsa-miR-133b, hsa-miR-143, hsa-miR-145, and endogenous control primers 5S rRNA, RNU1A1, and U6 snRNA or SNORD65 and SNORD110, were purchased from Exiqon. Reactions were performed according to the manufacturer instructions. Normalization was performed by using the mean of three endogenous reference genes. The RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas) was used to perform reverse transcription. Quantification of murine IGF1R mRNA was done by real-time PCR using the SYBR Premix exTaq II, Perfect Real Time (Takara, Lonza, Verviers, Belgium) according to the manufacturer instructions. Normalization was performed using the endogenous reference Gapdh gene expression level. Primers sequences were for Igf1r forward 5=-AGCTGATGTG-TACGTGCCTGATGA-3= and reverse 5=-TGATGGCCACTCTG-GTTTCGGGT-3=, and for Gapdh forward 5=-TGTGTCCGTCGTG-GATCTGA-3= and reverse 5=-CCTGCTTCACCACCTTCTTGA-3=. Real-time PCR reactions were carried out on a LightCycler480 (Roche).
Human cell lines. The human monocytic leukemia cell line THP-1 was grown in RPMI 1640 culture medium (Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza) and 1% penicillin and streptomycin (Lonza) at 37°C in 5% CO2 in a humidified incubator. For conditioned medium preparation, cells were stimulated with 1 g/ml of Ultra Pure Escherichia coli LPS (InvivoGen, Toulouse, France) for 24 h. Cells were harvested and supernatant was collected. Human colorectal adenocarcinoma cells (Caco-2) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin and streptomycin. Cells were cultured for 48 h in the presence of the conditioned medium of the LPS-stimulated THP-1 cells.
Western blotting. Proteins were extracted from 60 M tissue slices. In this case, colons were cryopreserved and embedded in Tissue-Tek (Gentaur) without fixation. Proteins were extracted in RIPA buffer [150 mM NaCl; 1% Nonidet P-40 (NP-40); 0.5% sodium deoxycholate, 2% SDS, 50 mM Tris pH 8, 1 mM EDTA pH 8] containing an anti-protease cocktail (Complete Protease Inhibitor Cocktail Tablets, Roche). Extracts were heated for 20 min at 98°C followed by 2 h at 60°C. Caco-2 cell proteins were extracted on ice by using the following lysis buffer: 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris, 0.1% SDS, containing Halt Protease Inhibitor Cocktail and Halt Phosphatase Inhibitor Cocktail (Fisher Scientific, Erembodegem, Belgium). Protein concentrations were measured using the MicroBCA kit (Pierce, Thermo Scientific). Protein extracts (20 g) were electrophoresed on 8% SDS-PAGE gels and subjected to classical Western blotting with an anti-MEKK5/ ASK1 (NH 2-terminal) rabbit monoclonal antibody (Epitomics, BioConnect, The Netherlands), anti-phospho-Akt (Ser473) antibody (Cell Signaling Technology, Danvers, MA), or anti-IGF1R rabbit polyclonal antibody (Sigma).
Immunohistochemistry. Cryopreserved Tissue-Tek (Gentaur)-embedded or FFPE 4-m colon sections mounted on SuperFrost Plus slides were used along with the DAKO EnVisionϩ Detection System-HRP (DAB) (Dako) according to the manufacturer's instructions.
The primary antibodies were the anti-NUFIP2 polyclonal rabbit antibody (Novus Biological, Bio-Connect, The Netherlands), anti-IGF1R (Ab-1161) rabbit polyclonal antibody (Sigma-Aldrich), and anti-phospho-Akt (Ser473) antibody (Cell Signaling Technology). Sections were counterstained with hematoxylin.
Mouse colon cell sorting. Cell sorting from mouse colon of mice was realized mainly as described (64) . In brief, the colon segment of the gastrointestinal tract was removed and flushed with Ca 2ϩ -and Mg 2ϩ -free HBSS. The colon was cut longitudinally, placed in Ca 2ϩ -and Mg 2ϩ -free HBSS containing 10% FBS-5 mM EDTA-25 mM HEPES, and shaken vigorously at 37°C for 30 min. The tissue was cut into 1-cm segments and incubated in digestion buffer containing 2.4 mg/ml collagenase A (Roche Diagnostics, Indianapolis, IN) and 0.2 mg/ml DNase I (Roche Diagnostics) in RPMI 1640 for 45 min on a shaker at 37°C. Following incubation, the cell aggregates were dissociated by filtering thorough a 19-gauge needle and 70-mm filter and centrifuged at 1,200 rpm for 20 min at 4°C. The supernatant was decanted and the cell pellet resuspended in PBS. Cells were labeled with the following antibodies from eBioscience company (Vienna, Austria): anti-CD326 (EpCAM) eFluor 450, anti-CD11b PerCP-cyanine 5.5, anti-Gr-1-PE (clone RB6 -8C5), anti-mouse CD45, and LY-6G (clone 1A8) FITC (STEMCELL Technologies, Grenoble, France). The FACSAria IIIu 4L SORP sorter was used (BD Biosciences, Erembodegem, Belgium).
Lentivirus and lentiviral transduction. A genomic sequence of 342 bp encompassing the hsa-pre-miR-223 and a shuffled sequence of the hsa-pre-miR-223 were cloned with use of the In-Fusion Advantage PCR Cloning Kit (Clontech) into a lentiviral plasmid derived from pLentiLox 3.7, under the control of the EF-1␣ promoter. The genomic sequence of hsa-miR-223 was amplified from Caco-2 cell gDNA with the following primers: forward, 5=-CCAGAACACAGGCCAAC-CTGGCCTGCTGCCCAGTGGAGGTTCC-3= containing a SfiI site; reverse, 5=-GACTGCATAAGCTAGCATGCACCCCAGAGCTGC-ATCGTTCCT-3= containing a SphI site. Two complementary DNA oligomers containing the shuffled sequence of hsa-pre-miR-223 were synthesized (Integrated DNA Technologies) and annealed. The sequence was scramble hsa-pre-mir-223/5Phos/TGGCCTAAGA-TATGGTTTCCCACTAACCGAGGAGTCAGCCGGGTAATTATG-CCATCCGAGTCTTTCCCTCGGAACCGTGATAACCGGTGCGC-GCTGAACTTTTGGCTGCCCGTACGCATG (120 bp) and contained a SfiI site at the 5= end and a XhoI site at the 3= end. VSV-G pseudotyped second generation lentivirus was produced by cotransfection of either the hsa-pre-miR-223 plasmid or the scr-pre-miR-223 plasmid described above, the VSV-G-containing plasmid psPAX2, and the packaging plasmid R8.91. Viruses were concentrated by high-speed centrifugation, and titers were determined by quantitative PCR (qPCR) using the qPCR Lentiviral titer kit from ABGood (Gentaur). Caco-2 cells (ATCC, LGC Standards) and LentiX cells (Fisher Scientific) were grown in DMEM (Lonza) supplemented with 10% FBS (Lonza). Caco-2 cells transductions were performed at MOI ϭ 20 on 7.5 ϫ 10 5 target cells with 8 g/ml polybrene (Sigma) at 37°C for 16 h.
Target Protector. miScript Target Protectors and negative control Target Protector were purchased from Qiagen (Leiden). According to predicted microRNA target and target downregulation scores (www. microrna.org, miRanda and miRSVR), two Target Protectors were designed: the first miScript Target protects the binding site for miR-223 in the IGF-1R mRNA 3=-UTR (GeneID: 3480 chr15: 99500881-99500902). The second miScript Target protects a common binding site for the miR-133a, miR133b, and miR-145 in the IGF-1R mRNA 3=-UTR (Chr15: 99504664 -99504685). Transfections of Caco-2 cells were performed with the HiPerfect Transfection Reagent according to the manufacturer's instructions.
RESULTS
miRNA expression profiles in the AOM/DSS mouse model of CAC. Three cycles of DSS subsequent to a single AOM pretreatment resulted in the development of colon tumors in nearly 100% of treated mice (Fig. 1, A and B) . From experimental days 65 to 100, tumors (mainly tubular adenomas with low-or high-grade dysplasia, average size 3-4 mm) were observed in the median and rectal part of the colon. Few tumors exhibited features of adenocarcinomas or infiltrated the submucosa. In agreement with previous studies, colonic tumors were never found in animals treated with three DSS cycles without AOM pretreatment (51) . These animals developed chronic colitis characterized by a thickened mucosa and muscularis, crypt loss, submucosal edema, immune cell infiltration, and disruption of the intestinal barrier (Fig. 1B ). Mice treated with AOM alone displayed normal colon histology, identical to that of PBS-treated mice.
To study the evolution of miRNA expression during the periods preceding and spanning tumor development, AOM/ DSS-treated mice were euthanized on experimental days 15, 29, 50 , and 65 ( Fig. 1C) . Whole colons were excised and processed for RNA/protein extraction and histological analyses. Animals treated with DSS, AOM alone, or vehicle (PBS) were euthanized on days 15 and 65.
MiRXplore microRNA microarray (miRBase 13.0) was used to establish miRNA expression profiles of whole colons from each group of mice. Twenty-one pairs of conditions were compared by the Mann-Whitney U-test (Supplemental Table  S1 ; supplemental material for this article is available online at the Journal website). We found that the expression of 71 miRNAs was affected by AOM/DSS treatment, most in a time-dependent manner ( Table 1 ). The greatest number of changes (53 miRNAs) occurred between days 15 and 65, when tumors developed. Thirty-five miRNAs were differentially regulated between days 50 and 65, whereas 25 miRNAs expression changes were identified when the effect of 65-day treatment with AOM/DSS was compared with PBS. The expression of 14 miRNAs was significantly different between mice treated with DSS or PBS for 65 days (Table 2) . DSS treatment for 15 days did not cause significant modulation of miRNA expression.
miRNA expression profiles under AOM/DSS conditions clearly differed from those obtained under DSS conditions (Tables 1 and 2 ). Of the 71 carcinogenesis-associated miRNAs identified, only eight were modified by DSS treatment, one of them showing opposite expression changes (mmu-miR-451). Five of the six chronic colitis-associated miRNAs (mmu-miR-133A, mmu-miR-133B, mmu-miR-143, mmu-miR-145, and mmu-miR-345-5p) were all negatively regulated, apart from the mmu-miR-21, which was upregulated. These results suggest that specific miRNA pools may regulate tumor growth.
To evaluate the relevance of our data to human pathology, we compared miRNAs differentially expressed in whole colon of AOM/DSS-treated mice with those associated with human CRC in the literature (Table 3) (3, 5, 6, 10, 16, 17, 20, 26, 39, 41, 45, 46, 48, 56, 57, 63) . As many as 24 miRNAs identified in the present AOM/DSS mouse model are reportedly associated with human CRC, with only a few differences in expression variation (up-or downregulation). Ten AOM/DSS-regulated miRNAs are altered in human IBDs (Table 4) (8, 9, 19, 33, 53, 60, 65) . Among these miRNAs, miR-146a, miR-146b, miR-150, and miR-223 are also differentially expressed upon mouse treatment with three DSS cycles, indicating that the inflammatory insult is sufficient to alter these miRNAs. Inversely, DSS treatment diminishes the expression of miR-133a, miR-143, and miR-145, which are associated with human CRC (30, 36) .
We next used miRCURY LNA Universal RT microRNA PCR to validate our microarray results. We chose eight miRNAs: miR-223, miR-142-5p, miR-148a, mir-34a, miR-29c, miR-146a, miR-193, and miR-216a ( Fig. 2A) , five of which were associated with human CRC pathology (Table 3) and three with human IBD (Table 4 ). For most of these miRNAs, the PCR analyses confirmed the microarray results. The expression levels of mir-34a, miR-142-5p, miR-146a, miR-148a, and miR-223 were significantly increased in whole colon at day 65 of AOM/DSS protocol compared with day 15, whereas a downregulation of miR-216a was observed under the same conditions ( Fig. 2A) . miR-142-5p, miR-146a, miR-148a, and miR-223 were significantly upregulated at day 65 compared with age-matched PBS-treated control mice. These PCR experiments also confirmed that three DSS cycles significantly upregulated miR-223 and miR-142-5p and downregulated miR-133a, mir-133b, miR-143, and miR-145 compared with control mice (Fig. 2B) .
Genes potentially regulated by pools of miRNA. miRNAs can be functionally included in networks. We investigated whether we could identify proteins involved in CAC on the basis of networking miRNA properties. To achieve this, we considered the modulated miRNAs as a whole, later referred to as the "miRNA climate." Using predicted miRNA-mRNA interactions (identified by combining results from TargetScan 5.0 and miRanda algorithms), we searched for genes that would be regulated by the "microRNA climate" of CAC more significantly than would occur by chance. The miRNAs were ranked such that more statistical importance was given to those presenting the highest number of significant modulations in our 21 comparisons (Supplemental Table S1 ). The miRNAs expressed but not modulated, and those that were not expressed, received an equal nearly null rank. Computational analyses (see MATERIALS AND METHODS for details) then identified 299 genes that were potentially regulated (P Ͻ0.05) by the miRNA climate expressed under our experimental conditions (Supplemental Table S2 ).
In an attempt to identify genes specifically regulated by carcinogenesis-associated miRNAs, miRNAs were ranked according to five AOM/DSS-based comparisons: AOM/DSS d65 vs. AOM/DSS d15, AOM/DSS d65 vs. PBS d65, AOM/DSS d15 vs. PBS d15, AOM/DSS d15 vs. AOM d15, and AOM/ Only mouse colon miRNAs significantly modified by AOM/DSS treatment (P Ͻ 0.05, see Table 1 ) are considered for comparison. IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease. Only mouse colon miRNA significantly modified by the AOM/DSS or DSS treatment (P Ͻ 0.05, see Table 1 and 2, respectively) are considered for comparison. *miRNA star. DSS d65 vs. AOM d65, where d represents day. The same ranking was performed for chronic colitis: miRNAs were ranked on the basis of the following comparisons: DSS d65 vs. DSS d15, DSS d65 vs. PBS d65, DSS d15 vs. PBS d15, DSS d15 vs. AOM d15, and DSS d65 vs. AOM d65. In all, 412 genes were identified as potentially regulated by DSS treatment (Supplemental Table S3 ) compared with 170 genes regulated by AOM/DSS (Supplemental Table S4 ). Interestingly, although the pools of miRNAs clearly differed between AOM/ DSS and DSS conditions, 139/170 AOM/DSS genes were found in the list of genes potentially regulated by DSS-related miRNAs.
Next, the Ingenuity Pathway software was used to identify the major pathways, biological functions, and protein networks related to the three lists of genes (Fig. 3) . The murine database was used to generate the analyses. Interestingly, cancer-associated biological functions were shared by the three lists of genes: abnormal morphology, cell cycle, growth and proliferation, and cell death. Some of the predicted targets were part of common networks involved in tissue development, cell death and survival, cell-to-cell signaling and interaction and cell morphology/movement. The main pathways included IGF-1, insulin receptor, PTEN, and PI3K/Akt signaling, as well as Myc and MAPK signaling. In addition, the genes potentially regulated by the DSS miRNA pool were involved in Wnt/␤-catenin signaling. These results suggest that both inflammation and carcinogenesis-associated miRNA climates regulate the expression of genes involved in cancer development.
Relationship between miRNA dysregulation and PI3K/Akt pathway in colorectal adenocarcinoma cells. Previous studies indicated that downregulation of miR-143/145 and miR-133a results in the activation of PI3K/Akt signaling and subsequent cancer cell proliferation (14, 49) . Since DSS decreases the expression levels of these miRNAs (Fig. 2B and Table 2 ), we wanted to assess whether an inflammatory environment alters their expression in cancer colon cells. We found that incubation of Caco-2 cells with conditioned medium of activated monocytic THP-1 cells downregulated miR-143/145 and miR133a in these cells (Fig. 4A ) and increased Akt phosphorylation (Fig. 4B) . Thus inflammation-triggered miRNA dysregulation could promote cancer cell proliferation through PI3K/Akt. miR-223 is upregulated in human CRC, IBD, and the IL-10 knockout mouse model of IBD (28) . In the AOM/DSS mouse model, we found that miR-223 was one of the main miRNAs showing significant upregulation during tumor growth ( Table  1) . Overexpression of miR-223 in Caco-2 cells was conducted via lentivirus infection. Transduced cells expressed lower levels of phosphorylated Akt than cells transduced with scramble miRNA (Fig. 4C) , depicting a link between alteration of miR-223 and PI3K/Akt signaling.
Activation of the PI3K/Akt signaling pathway during AOM/ DSS tumor growth. Inhibition of PI3K suppresses tumor growth in CRC (44) . To experimentally verify that the PI3K/ Akt signaling pathway is activated in our mouse model, we performed immunohistochemical analyses on mouse colon sections using an antibody directed against active Ser473-phosphorylated Akt. We found that AOM/DSS treatment induced Akt phosphorylation both in tumor and stromal cells (Fig. 5) . DSS treatment alone also increased phosphorylated Akt levels in aberrant crypt foci (Fig. 5) .
Expression changes of three selected candidate target genes in the CAC mouse model. From the lists of target genes potentially regulated by miRNA climates, we selected IGF-1R and MAP3K5 on the basis of the Ingenuity Pathway Analysis. In addition, NUFIP2 was chosen as a new gene candidate of unknown function in cancer development. Immunostaining Table S2 ) (A), by the pool of miRNAs modulated by AOM/DSS treatment (Supplemental Table S4 ) (B), or by the miRNA pool modulated by 3 successive DSS treatments (Supplemental Table  S3 ) (C). Only top pathways are shown, which correspond to the first 10 best P values.
was performed on colon sections from PBS-and AOM/DSStreated mice (Fig. 6A) . Under control conditions, IGF1R expression was detected in the cryptic epithelial cells, which did not change significantly upon AOM/DSS treatment at early stage of tissue transformation. In tumors, IGF1R expression was significantly decreased, whereas staining of stromal and inflammatory cells was observed between the crypts. The expression of Nufip2 protein in the colon layers was globally increased by AOM/DSS treatment and, to a larger extent, in tumors. AOM/DSS treatment caused a marked decrease of Map3k5 expression, as shown by Western blotting on whole colon extracts (Fig. 6B) and immunohistochemistry (data not  shown) .
These data support tight regulation of the three selected genes during tumor development, which is likely to depend on CAC-related changes in the miRNA climate. To assess whether IGF1R is indeed regulated by miRNAs in colon cells, IGF1R expression was analyzed in Caco-2 cells overexpressing miR-223. Transduced cells expressed lower levels of IGF1R than cells transduced with scramble miRNA (Fig. 6C) . The use of a miScript Target Protector interfering with the miR-223-IGF1R mRNA 3=-UTR interaction could rescue IGF1R protein expression in Caco-2 cells, therefore demonstrating that miR-223 directly targets IGF1R (Fig. 6D) . On the contrary, a miScript Target that protects a common binding site for miR-133a, miR133b, and miR-145 in the IGF1R mRNA 3=-UTR hardly impacted on IGF1R protein expression. In mice, we observed a striking inverse relationship between changes of IGF1R mRNA and miR-223 expression during AOM/DSS-induced carcinogenesis and in tumors compared with adjacent tissues (Fig. 6E) .
Cell-type-specific expression of miRNAs in AOM/DSS mouse colons. miRNA function can vary in a cell-type-specific manner, especially considering colon leukocytes and transformed epithelial cells. To determine whether these cells differentially expressed selected miRNAs, we sorted myeloid cells (Gr1ϩ cells), and epithelial cells (CD326ϩ) from mouse colons at experimental days 15, 29, 50 , and 65 (Fig. 7A) . In agreement with previous studies (68) , early infiltration of myeloid cells of monocytic (Ly6CϩCD11bϩ) and granulocytic (Ly6GϩCD11bϩ) origin was observed (Fig. 7B) . We then assessed the expression of miR-143/145, miR-133a, and miR-223 in sorted Gr1ϩ myeloid and CD326ϩ epithelial cells (Fig. 7C) . In epithelial cells, miR-143/145 expression quickly decreased at day 15, fluctuated between days 15 and 50, and was downregulated at day 65 when tumors are formed. Epithelial miR-133a was rapidly downregulated at day 15 and remained unchanged until day 65. These three miRNAs were also expressed in myeloid cells. miR-133a expression profile was mainly unchanged during tumor development, whereas a . E: qPCR analyses of IGF1R mRNA expression and miR-223 expression in whole colons of AOM/DSS-treated mice for 65 days and in tumors resected at day 100. Expression levels measured in healthy tissues (Adj. Tis.) were arbitrarily set to 100 for each set of experiments (n ϭ 5).
downregulation of miR-145 and miR-143 was observed. miR-223 expression was much higher in myeloid cells. In these cells, a time-dependent miR-223 expression profile was observed that followed the same pattern as in whole colon (Fig.  6E) . Epithelial cells displayed a distinct expression pattern, characterized by an early upregulation occurring at day 15, followed by a downregulation at day 65.
DISCUSSION
Using a well-established mouse model of CAC, we analyzed the miRNA expression changes accompanying chronic inflammation-dependent tumor development. We identified important inflammation-and carcinogenesis-related miRNAs potentially affecting target genes involved in the PI3K/Akt signaling pathway, which may, therefore, represent molecular links between inflammation and cancer. In vitro experiments performed in human colorectal adenocarcinoma cells confirmed a relationship between miR-133a, miR-143, miR-145, and miR-223 dysregulation and alteration of PI3K/Akt signaling. In addition, we found that miR-223 could directly target IGF1R to regulate this pathway.
We chose to perform a miRNA microarray analysis on RNA samples extracted from mouse whole colon because 1) both immune and intestinal cells are expected to be involved in carcinogenesis, 2) we wanted to assess miRNA variations at time points preceding tumor development, and 3) secreted miRNA are believed to act on different cell types in a paracrine manner (11) . The majority of miRNA variations mainly occurred between experimental days 15 and 65, and between days 50 and 65, emphasizing the critical importance of events preceding tumor formation.
In a similar study, Necela et al. (47) investigated miRNA expression in colorectal tumors from two mouse models: one of genetic origin (APC ϩ/min mice), and the second of inflammation-related origin (12 cycles of DSS treatment). They found that miR-215, miR-137, miR-708, miR-31, and miR135b were differentially expressed in APC tumors, whereas the expression of miR-215, miR-133a, miR-467d, miR-218, miR-708, miR-31, and miR-135b varied in colitis-associated tumors. Among these miRNAs, miR-133a was the only one identified in the present study. In a more recent study, Gao et al. (21) used a similar AOM/DSS mouse model to ours, in which they analyzed mRNA and miRNA expression profiles. Their study revealed alterations of miRNAs involved in the inflammatory response and in metabolism; in addition, most differentially expressed genes were enriched in metabolic pathways/processes, pointing to a close relationship between metabolic and inflammatory genes in CAC. We identified only a few miRNA reported in this study (miR-21, miR-34a, miR99a, miR-193), probably owing to differences of protocol and/or mouse genetic background (BalB/c vs. C57BL/6). In contrast to our study, the authors of the two studies used scraped colonic epithelial cells at only one final time point when the tumors were already formed. The miRNA identified by Necela et al. and Gao et al. were most likely specific to the epithelial compartment; however, the studies of Greten et al. (23) and Grivennikov et al. (24) showed that immune cells play a role that is as important as that of epithelial cells in the development of CAC. Moreover, our study suggests that celltype-specific early variations of miRNA expression, occurring before tumor formation, may contribute to carcinogenesis.
Many groups highlight the cooperative effects of several miRNAs, showing that integrating predicted targets and functional information could identify miRNA clusters and concurrently reveal their underlying functions (67) . Yuan et al. (69) demonstrated that clustered miRNAs jointly regulate proteins that are in close proximity within a protein interaction network, and that the amount of coregulation between proteins is negatively correlated with their distance from each other within the network. On the basis of these studies, we considered miRNA modulation in our system as a whole and exploited their networking properties to identify the targets that they most likely share. We postulated that these genes could be of a particular interest in CAC pathology.
We identified 170 genes, which are potentially regulated by the "CAC climate" of miRNAs. Using the pool of DSSinduced miRNAs, a list of 421 putative target genes was identified. Interestingly, 139 of the 170 CAC-related genes were on the list of DSS-related genes. Only 31 genes were putative targets of a "carcinogenesis-specific miRNA climate." Moreover, when the 421 DSS-specific genes were analyzed in terms of pathway involvement and function by use of Ingenuity Pathway software, they appeared to be involved in cancer, apoptosis, and proliferation in the same manner as the carcinogenesis subset of target genes. miRNA-induced inflammation may thus affect many more genes than expected, thereby contributing to carcinogenesis. For instance, genes potentially regulated by the DSS miRNA pool were involved in Wnt/␤-catenin signaling, a pathway dysregulated in AOM/DSS-induced tumors (42, 61) and in human CRC. In addition, the target genes of the Wnt/␤-catenin signaling pathway include the cellular myelocytomatosis oncogene (c-Myc), similarly found to be dysregulated in mouse and human tumors. c-Myc functions as a global mediator of the oncogenic process, linking the seemingly heterogeneous pool of molecular mechanisms that underlies cancer development (37) . Overall, the predicted targets of DSS and AOM/DSS miRNA climates were part of common cancer-related networks, and the main pathways included IGF-1, insulin receptor, PTEN, and PI3K/Akt signaling, as well as Myc and MAPK signaling. These findings are in agreement with the previously reported function of PI3K in colitis and CAC (22, 32, 70) . Immunohistochemical analyses indeed confirmed that this pathway is activated during AOM/DSS tumor growth. Interestingly, we found that chronic DSS treatment downregulates miR-133a, miR-143, and miR-145. These miRNA were also downregulated in macrodissected tumors compared with adjacent tissues (data not shown). Downregulation of miR-133a and miR-143/145 is reported in human CRC (38, 50, 54) and results in PI3K/Akt signaling activation in breast (14) and bladder (49) cancer cells, respectively. Accordingly, we found that conditioned medium from inflammatory cells decreases the expression of these miRNA and increased Akt phosphorylation in colorectal adenocarcinoma Caco-2 cells. Validated targets of miR-143 and miR-145 that may affect the PI3K/Akt pathway include KRAS and RREB1 (36), miR-143 could directly target AKT, and miR-145 targets ILK (49) . miR-133a possesses many targets that have been involved in cancer (50) . Particularly, this miRNA can directly target IGF1R, as shown in myoblasts (31) . IGF1R mediates PI3K/Akt activation. Deregulation of IGF1R activity is implicated in tumor cell proliferation in many human malignant diseases, including CRC (1). Currently, no data are available regarding the role of IGF1R in the AOM/DSS mouse model. The study by Knowlton et al. (38) indicates that miRNA alterations modify kinase activation in the IGF-1 pathway and correlate with CRC stage and progression in patients. Qian et al. (54) have shown that miR-143 directly targets IGF1R, and IGF1R expression inversely correlated with miR-143 levels in human CRC specimens. In our study, interfering with miR-143-IGF1R mRNA 3=-UTR interaction hardly impacted on IGF1R expression, suggesting that miR-143 can affect the PI3K/Akt pathway independently of IGF-1R signaling (see above).
In the present mouse model, we found that miR-223 is one of the main miRNA showing strong upregulation when AOM/ DSS-induced tumors are formed. Strikingly, a clear downregulation is observed during the periods preceding tumor formation (days 15 to 50). miR-223 is upregulated in human CRC and IBD (Tables 3 and 4 ) and in mouse models of IBD (55) . miR-223 is fairly specific for the hematopoietic lineage where it acts to limit inflammation and prevent oncogenic myeloid transformation (28) . In our study, colon cell sorting enabled us to confirm high expression of miR-223 in myeloid cells compared with epithelial cells. Differential expression patterns were observed in the two cell types during tumor development. miR-223 has been involved in solid cancers in which opposing roles in regulating migration and invasion of cancer cells have been described (28) . Injection of HeLa cells overexpressing miR-223 into nude mice suppressed proliferation and tumor growth (35) . Interestingly, this suppression was mainly caused by reducing expression of the miR-223 target IGF1R and downstream Akt/mTOR/p70S6K signaling, which was also seen in leukemia and hepatoma cell lines (25) . In our study, we observed a striking inverse relationship between changes of Igf1r mRNA and miR-223 expression in whole colon of AOM/DSS-treated mice and in tumors compared with adjacent tissues. The expression of miR-223 is indeed dramatically increased at stages of tumor growth when Igf1r expression decreases. Immunohistochemistry revealed that treatment with AOM/DSS decreased IGF1R expression in tumor cells whereas expression was detected in stromal and infiltrating immune cells. Expression of the Igf1r gene thus appeared to be tightly controlled during carcinogenesis in a cell-type-specific manner. We wondered whether IGF1R could be a direct target of miR-223 in colon cancer cells. Using two methods, lentivirus-based overexpression and transfection of Target Protectors, we found that IGF1R expression was directly regulated by miR-223 in colorectal adenocarcinoma cells. Colon cancer cells overexpressing miR-223 also displayed increased levels of phosphorylated Akt, indicating that targeting IGF1R with miR-223 can inhibit PI3K/Akt activation. Evaluating the importance of cell-type-specific miR-223 regulation in the development of colitis-associated cancer requires further in vivo investigation.
To validate our computational method, two other genes were selected from our list of 170 genes potentially regulated by carcinogenesis-related miRNAs. These genes code for the Map3k5 (Ask1) MAP3 kinase and for the Nufip2 RNA binding protein. Map3k5 is a ubiquitously expressed MAP3 kinase activated by various stress stimuli, including reactive oxygen species. Map3k5 activates the JNK and p38 signaling pathways and induces oxidative stress and cytokine-induced apoptosis. Map3k5 is also implicated in a variety of cellular functions, including immune responses (29, 34) . Using a very similar CAC mouse model, Hayakawa et al. (29) identified a protective role for Map3k5 against DSS-induced inflammation and AOM/ DSS-induced tumors, and demonstrated that Map3k5Ϫ/Ϫ mice develop more numerous and larger tumors than wild-type mice during increased colonic inflammation. In accordance with this study, we showed reduced Map3k5 expression in whole colon of AOM/DSS-treated mice, which confirms a tumor suppressor role of this protein. Interestingly, Map3k5 is a target of miR-17 (12) that was upregulated when tumors developed in our mouse model (Table 1) . Nufip2 is a RNA binding protein involved in fragile X mental retardation. Little is known about its function. The 3=-UTR of Nufip2 mRNA is unusually long, encompassing 8,231 bp (NCBI Gene ID: 68564). In humans, the 3=-UTR of Nufip2 can bind up to 19 miRNAs (TarBase, DIANA Lab) (62) . The expression of Nufip2 protein was markedly increased in the colons of mice treated with AOM/DSS and remained elevated in tumors. Further investigations are required to elucidate the role of this protein in CRC and to validate regulation of its expression by miRNAs.
In conclusion, on the basis of our microarray data, networking, and target prediction analyses, as well as in vitro and in vivo validation experiments, we propose a model in which chronic inflammation could induce miRNA dysregulation in colon cells and/or leukocytes that would affect proteins involved in the PI3K/Akt signaling pathway, thereby contributing to cancer cell proliferation (Fig. 8) .
Thus variations in miRNA expression within a biological system can be exploited to generate lists of potential target genes by a ranking and permutation method. In our study, we demonstrate that this method is a valuable tool for identifying novel epigenetic mechanisms that regulate the genes or signaling pathways involved in cancer pathobiology.
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